Literature DB >> 35023038

Preoperative predictors of non-transplantable recurrence after resection for early-stage hepatocellular carcinoma: application in an East Asian cohort.

Wei-Feng Li1, Yi-Hao Yen2, Yueh-Wei Liu1, Chih-Chi Wang3, Chee-Chien Yong1, Chih-Che Lin1.   

Abstract

A French study found that three preoperative factors (i.e. alpha-fetoprotein (AFP) > 100 ng/ml, image-diagnosed tumor number > 1, and cirrhosis) could predict non-transplantable recurrence (NTR) after liver resection (LR) for early-stage hepatocellular carcinoma (HCC). We aimed to evaluate whether this model could be applicable in an East Asian cohort from a country in which the majority of patients undergo living donor liver transplantation (LT). This retrospective study enrolled consecutive patients who underwent LR for transplantable HCC between 2011 and 2018 in our institution. The occurrence of NTR after LR was analyzed in a competing risks analysis, with death and transplantable recurrence as competing events. A total of 309 patients were included. The five-year overall survival and recurrence-free survival were 79.0% and 51.4%, respectively (median follow-up: 32.0 months). Recurrence was noted in 94 (30.4%) patients. NTR was noted in 35 (11.3%) patients. Univariate analysis showed that cirrhosis (sub-distribution hazard ratio (SHR) = 2.301, 95% CI = 1.046-5.065; p = 0.038) and image-diagnosed tumor number > 1 (SHR = 2.32; 95% CI = 1.11-4.86; p = 0.026) were associated with NTR, whereas AFP > 100 ng/ml (SHR = 1.56; 95% CI = 0.59-4.10; p = 0.37) was not associated with NTR. In the presence of 0, 1, and 2 factors (i.e. cirrhosis or image-diagnosed tumor number > 1), the NTR rates were 7.2%, 10.8%, and 29.0%, respectively. The results showed that the French model was applicable to our cohort. In the presence of two factors (i.e. cirrhosis and image-diagnosed tumor number > 1), risks and benefits of upfront LT could be discussed with the patient and the living donor.
© 2021. Italian Society of Surgery (SIC).

Entities:  

Keywords:  Alpha-fetoprotein; Hepatocellular carcinoma; Liver resection; Liver transplantation

Mesh:

Substances:

Year:  2022        PMID: 35023038     DOI: 10.1007/s13304-021-01220-2

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  26 in total

1.  Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach.

Authors:  Ying-Chun Shen; Chiun Hsu; Li-Tzong Chen; Chia-Chi Cheng; Fu-Chang Hu; Ann-Lii Cheng
Journal:  J Hepatol       Date:  2010-03-24       Impact factor: 25.083

2.  Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis.

Authors:  David Fuks; Safi Dokmak; Valérie Paradis; Momar Diouf; François Durand; Jacques Belghiti
Journal:  Hepatology       Date:  2012-01       Impact factor: 17.425

3.  Meta-analysis: the efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma.

Authors:  J S-W Wong; G L-H Wong; K K-F Tsoi; V W-S Wong; S Y-S Cheung; C-N Chong; J Wong; K-F Lee; P B-S Lai; H L-Y Chan
Journal:  Aliment Pharmacol Ther       Date:  2011-03-24       Impact factor: 8.171

4.  Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study.

Authors:  Samer Gawrieh; Lara Dakhoul; Ethan Miller; Andrew Scanga; Andrew deLemos; Carla Kettler; Heather Burney; Hao Liu; Hamzah Abu-Sbeih; Naga Chalasani; Julia Wattacheril
Journal:  Aliment Pharmacol Ther       Date:  2019-09-01       Impact factor: 8.171

5.  Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.

Authors:  Jorge A Marrero; Laura M Kulik; Claude B Sirlin; Andrew X Zhu; Richard S Finn; Michael M Abecassis; Lewis R Roberts; Julie K Heimbach
Journal:  Hepatology       Date:  2018-08       Impact factor: 17.425

6.  Liver Resection for Early Hepatocellular Carcinoma: Preoperative Predictors of Non Transplantable Recurrence and Implications for Treatment Allocation.

Authors:  Maximiliano Gelli; Mylène Sebagh; Raphaël Porcher; Elena Romanelli; Eric Vibert; Antonio Sa Cunha; Denis Castaing; Olivier Rosmorduc; Didier Samuel; René Adam; Daniel Cherqui
Journal:  Ann Surg       Date:  2020-11       Impact factor: 12.969

7.  Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation.

Authors:  Olivier Scatton; Stéphane Zalinski; Benoit Terris; Jérémie H Lefevre; Alessandra Casali; Pierre-Philippe Massault; Filomena Conti; Yvon Calmus; Olivier Soubrane
Journal:  Liver Transpl       Date:  2008-06       Impact factor: 5.799

8.  Living donor liver transplantation for hepatocellular carcinoma: a single-center experience in Taiwan.

Authors:  Allan Concejero; Chao-Long Chen; Chih-Chi Wang; Shih-Ho Wang; Chih-Che Lin; Yueh-Wei Liu; Chin-Hsiang Yang; Chee-Chien Yong; Tsan-Shiun Lin; Bruno Jawan; Tung-Liang Huang; Yu-Fan Cheng; Hock-Liew Eng
Journal:  Transplantation       Date:  2008-02-15       Impact factor: 4.939

9.  Characteristics and etiologies of hepatocellular carcinoma in patients without cirrhosis: When East meets West.

Authors:  Yi-Hao Yen; Yu-Fan Cheng; Jing-Houng Wang; Chih-Che Lin; Chih-Chi Wang
Journal:  PLoS One       Date:  2021-01-13       Impact factor: 3.240

10.  Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.

Authors:  V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari
Journal:  N Engl J Med       Date:  1996-03-14       Impact factor: 176.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.